<p><strong>Soligenix, Inc</strong>. (NASDAQ: SNGX) 周三宣布了其正在进行的 SGX302（合成高超敏）针对轻度至中度银屑病的 IIa 期试验的扩展结果。</p>
<p>在本次扩展（第 3 组）研究的探索性阶段中，额外招募了四名患者，并使用改进的合成高超敏外用凝胶配方进行了治疗。</p>
<p>该凝胶配方专门设计用于提高在皮肤大面积应用时的便利性。</p>
<p>SGX302 凝胶疗法在所有患者中耐受良好，没有发现与药物相关的 不良事件。</p>
<p>在三名可评估患者中（因个人原因中断治疗的一名患者），在研究者全球评估（IGA）、银屑病活动和严重指数（PASI）、简化银屑病指数、皮肤科生活质量指数和 Skindex-29 问卷中均有改善。</p>
<p>一名患者在 IGA 中达到了 “几乎清晰” 的疾病状态，这被视为银屑病治疗成功的标准临床指标，其 PASI 评分显著改善，超过 50%。</p>
<p><strong>另请阅读: 强生、主角研究显示银屑病试验中的皮肤清除效果优越</strong></p>
<p>这些结果与之前的药膏配方获得的结果非常相似或有所改善，正如预期的那样，考虑到两种配方的释放特性相似以及凝胶的应用便利性增强。</p>
<p>研究的初步探索阶段已确认 SGX302 改善银屑病损伤，这与光动力疗法在银屑病中的普遍成功一致，并且耐受良好，可能为银屑病中较厚的损伤提供一种非致癌、非诱变的治疗方案。</p>
<p><strong>SNGX 股价动态：</strong> Soligenix 股票在周三发布时下跌 21.05%，报 $1.21。</p>
<p><strong>下一步阅读：</strong></p>
<ul>
<li><strong>辉瑞、默克再次变得无聊——这正是 2026 年投资者重新关注的原因</strong></li>
</ul>
<p><em>照片来源: Shutterstock</em></p>

SNGX

<p>Soligenix 宣布了 SGX302 凝胶在银屑病治疗中的积极 2a 期扩展结果，显示出皮肤评分改善和良好的耐受性。新的凝胶配方增强了使用的便利性，且未报告不良事件。一名患者达到了 “几乎清晰” 的状态，PASI 评分显著改善。该凝胶的结果与之前的配方相似或更好，确认了其作为非致癌性银屑病治疗的潜力</p>

<p><strong>Soligenix, Inc</strong>. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to- moderate psoriasis.</p>
<div class="lb-trans"><p><strong>Soligenix, Inc</strong>. (NASDAQ: SNGX) 周三宣布了其正在进行的 SGX302（合成高超敏）针对轻度至中度银屑病的 IIa 期试验的扩展结果。</p>
</div><p>In this extension (Cohort 3) of the exploratory phase of the study, an additional four patients were enrolled and treated with an improved topical gel formulation of synthetic hypericin.</p>
<div class="lb-trans"><p>在本次扩展（第 3 组）研究的探索性阶段中，额外招募了四名患者，并使用改进的合成高超敏外用凝胶配方进行了治疗。</p>
</div><p>The gel formulation was specifically designed to improve ease of application to larger areas of the skin.</p>
<div class="lb-trans"><p>该凝胶配方专门设计用于提高在皮肤大面积应用时的便利性。</p>
</div><p>SGX302 gel therapy was well tolerated by all patients with no drug-related adverse events identified.</p>
<div class="lb-trans"><p>SGX302 凝胶疗法在所有患者中耐受良好，没有发现与药物相关的 不良事件。</p>
</div><p>On average, over the three evaluable patients (one patient discontinued for personal reasons), there were improvements in the Investigator Global Assessment (IGA), the Psoriasis Activity and Severity Index (PASI), the simplified psoriasis index, the dermatology life quality index, and the Skindex-29 questionnaire.</p>
<div class="lb-trans"><p>在三名可评估患者中（因个人原因中断治疗的一名患者），在研究者全球评估（IGA）、银屑病活动和严重指数（PASI）、简化银屑病指数、皮肤科生活质量指数和 Skindex-29 问卷中均有改善。</p>
</div><p>One patient achieved a disease status of “Almost Clear” using the IGA, which is considered a standard clinical measure for treatment success in psoriasis, with a substantial improvement in their PASI score, exceeding 50%.</p>
<div class="lb-trans"><p>一名患者在 IGA 中达到了 “几乎清晰” 的疾病状态，这被视为银屑病治疗成功的标准临床指标，其 PASI 评分显著改善，超过 50%。</p>
</div><p><strong>Also Read: Johnson &amp; Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials</strong></p>
<div class="lb-trans"><p><strong>另请阅读: 强生、主角研究显示银屑病试验中的皮肤清除效果优越</strong></p>
</div><p>These outcomes were very similar to or improved relative to those obtained with the previous ointment formulation, as expected given the comparable release characteristics of the two formulations and the enhanced ease of application of the gel.</p>
<div class="lb-trans"><p>这些结果与之前的药膏配方获得的结果非常相似或有所改善，正如预期的那样，考虑到两种配方的释放特性相似以及凝胶的应用便利性增强。</p>
</div><p>The initial exploratory phase of the study has confirmed that SGX302 improves psoriasis lesions, consistent with the general success of photodynamic therapies in psoriasis, and is well tolerated, potentially providing a non-carcinogenic, non-mutagenic treatment for the thicker lesions found in psoriasis.</p>
<div class="lb-trans"><p>研究的初步探索阶段已确认 SGX302 改善银屑病损伤，这与光动力疗法在银屑病中的普遍成功一致，并且耐受良好，可能为银屑病中较厚的损伤提供一种非致癌、非诱变的治疗方案。</p>
</div><p><strong>SNGX Price Action:</strong> Soligneix stock is down 21.05% at $1.21 at publication on Wednesday.</p>
<div class="lb-trans"><p><strong>SNGX 股价动态：</strong> Soligenix 股票在周三发布时下跌 21.05%，报 $1.21。</p>
</div><p><strong>Read Next:</strong></p>
<div class="lb-trans"><p><strong>下一步阅读：</strong></p>
</div><ul>
<li><strong>Pfizer, Merck Are Boring Again — And That’s Exactly Why 2026 Investors Are Circling Back</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>辉瑞、默克再次变得无聊——这正是 2026 年投资者重新关注的原因</strong></li>
</ul>
</div><p><em>Photo: Shutterstock</em></p>
<div class="lb-trans"><p><em>照片来源: Shutterstock</em></p>
</div>

Soligenix 银屑病试验的扩展研究显示新型凝胶取得更好效果